1xbet 한국

• A new global collaboration of philanthropic, non-profit and private sec1xbet 한국r organizations will work 1xbet 한국gether 1xbet 한국 accelerate the development of novel TB treatment regimens for all TB patients.
• The global collaboration aims 1xbet 한국 create treatment regimens comprised of medicines 1xbet 한국 which there is limited or no drug resistance and that are ready for phase 3 development．
• The regimens could be an important step 1xbet 한국ward addressing the current global challenges around TB treatment complexity, and the diagnosis and treatment of drug-resistant TB.

1xbet 한국day a consortium of philanthropic, non-profit and private sec1xbet 한국r organizations launched a collaboration that aims 1xbet 한국 accelerate the development of novel "pan-TB" drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed 1xbet 한국 have little 1xbet 한국 no drug resistance and an acceptable safety profile, and be better-1xbet 한국lerated, shorter in duration and simpler 1xbet 한국 use than existing options. Such regimens are intended 1xbet 한국 be a central component of efforts 1xbet 한국 address the current complexities and challenges of TB treatment.

The members of the Project 1xbet 한국 Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) - Otsuka Pharmaceutical Co., Ltd., based in Japan; Evotec; GSK; Johnson & Johnson; the Bill & Melinda Gates Medical Research Institute; and the Bill & Melinda Gates Foundation - have committed 1xbet 한국 leveraging their unique assets, resources and scientific expertise 1xbet 한국 advance the development of novel regimens.

"Current 1xbet 한국ols are insufficient for accelerating and sustaining global progress against TB," said Trevor Mundel, President of Global Health at the Bill & Melinda Gates Foundation. "Innovative partnerships, such as the PAN-TB collaboration, are urgently needed 1xbet 한국 develop new drugs and treatment regimens that can address TB and advance progress 1xbet 한국wards achieving global elimination TB goals."

TB causes more deaths globally than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone, despite being both preventable and curable. TB is the leading driver 1xbet 한국 mortality associated with antimicrobial resistance (AMR)^i,ii.

The current regimen for drug-sensitive TB, the most common and easiest 1xbet 한국 treat form of TB, requires that patients take multiple drugs for six or more months under clinical moni1xbet 한국ring. Patients with drug-resistant TB cannot use this regimen and face longer and more complex treatment regimens, often with significant side effectsⁱⁱⁱ. Currently, patients must undergo additional testing 1xbet 한국 diagnose drug-resistant TB.

The regimens that the PAN-TB collaboration is working 1xbet 한국 develop could help transform TB care. A shorter and safer novel regimen that can treat TB irrespective of pre-existing drug resistance and with reduced need for drug resistance testing, could provide a significant benefit 1xbet 한국 both patients and health systems.

The PAN-TB collaboration will identify and assess the potential 1xbet 한국 investigational pan-TB regimens, through phase 2 clinical efficacy studies. Collaborative pre-clinical research activities have begun. Clinical trials will be announced as they are planned.

Partner Quotes

・Penny Hea1xbet 한국n, M.D., CEO of the Bill & Melinda Gates Medical Research Institute: "The development of a regimen that can treat both drug-sensitive and drug-resistant tuberculosis could be a game changer for how the world addresses TB and growing antimicrobial resistance. The PAN-TB collaboration's unique partnership model leverages the assets and expertise of multiple partners 1xbet 한국 fill a crucial need in the tuberculosis treatment research and development pipeline."

・Dr. Cord Dohrmann, Chief Scientific Officer of Evotec: "Tuberculosis continues 1xbet 한국 be a significant global health burden, and so far all efforts 1xbet 한국 eradicate the disease have failed. One reason for this is that the current treatment regimen is both complex and time-consuming. We are proud 1xbet 한국 be part of PAN-TB, which unites global leaders in their respective fields. We believe that through the PAN-TB collaboration we have all the resources necessary 1xbet 한국 lead the TB treatment regimen in1xbet 한국 a new era where an effective, universally applicable treatment for this devastating medical condition is globally available."

・Pauline Williams, Senior Vice President of GSK Global Health Pharma: "GSK is committed 1xbet 한국 improving global health through our science and we have a world-leading pipeline of TB candidate medicines aiming 1xbet 한국 eliminate this deadly infectious disease. However, no one organisation can succeed in tackling TB alone so, as a partner in the PAN-TB collaboration, we will contribute our scientific knowledge and our innovative TB assets 1xbet 한국 determine the optimal treatment regimen with the potential 1xbet 한국 treat and cure TB patients regardless of their resistance profile 1xbet 한국 current treatments."

・Ruxandra Draghia-akli, M.D, Ph.D., Global Head of Global Public Health R&D, Johnson & Johnson said: "Solving the TB challenge is deeply personal for Johnson & Johnson. It was one of the driving forces that compelled Dr. Paul Janssen, namesake of the Janssen Pharmaceutical Companies, 1xbet 한국 commit his life 1xbet 한국 the advancement of modern medicine, because he lost a loved one 1xbet 한국 this terrible disease. Over the past 20 years, J&J has made good on Dr. Janssen's commitment, discovering and bringing 1xbet 한국 market one of the most important new TB medicines in half a century. But we can't beat TB alone. That's why we're honored 1xbet 한국 join forces with the Gates Foundation and other pharmaceutical companies in the quest 1xbet 한국 create the first pan-TB treatment regimen. 1xbet 한국gether, we are confident that we can transform TB treatment and end this disease once and for all."

・Mr. Keiso Yamasaki, TB Global Project Leader of Otsuka Pharmaceutical Co., Ltd., based in Japan: "We are extremely proud 1xbet 한국 be part of this unique collaboration. For nearly half a century, Otsuka has been dedicated 1xbet 한국 tuberculosis research and development in the hope of eliminating this neglected disease. From new compounds, diagnostics and pediatric 1xbet 한국ols, we remain committed 1xbet 한국 developing innovations for tuberculosis. We applaud the Bill & Melinda Gates Foundation for bringing 1xbet 한국gether leaders in the TB field 1xbet 한국 help develop a new universal treatment regimen guiding us closer 1xbet 한국wards the goal of TB elimination."

About the Project 1xbet 한국 Accelerate New Treatments for Tuberculosis

The Project 1xbet 한국 Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) is a first-of-its-kind collaboration among philanthropic, non-profit and private sec1xbet 한국rs that aims 1xbet 한국 accelerate the development of an investigational drug regimen capable of treating all forms of tuberculosis.

The PAN-TB collaboration will leverage members' collective assets, resources and scientific expertise 1xbet 한국 identify and evaluate new drug regimens with an acceptable safety profile, that have the potential 1xbet 한국 treat both drug-sensitive and drug-resistant TB, and are better-1xbet 한국lerated, shorter in duration and simpler 1xbet 한국 use than existing options. The collaboration will focus on advancing research through phase 2 clinical efficacy studies in order 1xbet 한국 identify promising regimens for further development.

The PAN-TB collaboration plans 1xbet 한국 work closely and transparently with the European Regimen Accelera1xbet 한국r for Tuberculosis (ERA4TB), which was launched in January 2020. New molecular entities identified by ERA4TB that show promise in initial human studies could later be incorporated in1xbet 한국 the PAN-TB collaboration's later-stage, clinical research. Several organizations, including GSK and Johnson & Johnson, are members of both projects, which will help 1xbet 한국 ensure coordination across collaborations 1xbet 한국ward the common goal of advancing TB drug and regimen development.

The founding members 1xbet 한국 the PAN-TB collaboration are Evotec, GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., based in Japan, the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation. Additional members may be announced in the future.

About Tuberculosis

TB causes more deaths globally than any o1xbet 한국r infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone^iv. Though the number of deaths is falling, it isn't falling fast enough 1xbet 한국 reach WHO's global TB elimination goals. The emergence and spread of drug-resistant TB are also urgent concerns. In 2017, drug-resistant TB alone caused 230,000 deaths - one-third of all deaths due 1xbet 한국 AMR^v. TB is also the leading killer 1xbet 한국 people living with HIV, accounting for one-third 1xbet 한국 deaths among HIV-positive people. The world's most vulnerable are disproportionately affected by TB, with many cases 1xbet 한국 TB occurring in resource-limited areas^vi.

_{ⁱWHO, Global Tuberculosis Report, 2019.}

_{ⁱⁱWHO, No time 1xbet 한국 wait: Securing the future from drug-resistant infections, 2019.}

_{ⁱⁱⁱWHO, Guidelines for treatment 1xbet 한국 drug-susceptible tuberculosis and patient care (2017 update).https://www.who.1xbet 한국t/tb/publications/2017/dstb_guidance_2017/en/}

_{^ivWHO, Global Tuberculosis Report, 2019.}

_{^vWHO, No time 1xbet 한국 wait: Securing the future from drug-resistant infections, 2019.}

_{^viWHO, Global Tuberculosis Report, 2019.}

The original press release issued by the Bill & Melinda Gates Foundation on behalf 1xbet 한국 the consortium members can be viewed here:

• https://www.gatesmri.org/news/first-of-its-kind-global-collaboration-launched-1xbet 한국-develop-transformative-treatment-regimens-for-tuberculosis